Catalyst
Slingshot members are tracking this event:
Alexion (ALXN) Initiates Dosing in Phase I Study Evaluating ALXN1210 Administered Subcutaneously to Healthy Volunteers
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALXN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 27, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Dosing Initiation, Phase 1, Alxn1210, Subcutaneous, Healthy Volunteers, Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome
